MetrioPharm AG

MetrioPharm AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with R&D operations in Berlin, Germany. The company focuses on developing a platform of first-in-class, self-regulating immunomodulators that target dysregulated mitochondrial metabolism in macrophages. By normalizing oxidative stress without suppressing the immune system, their lead compound, MP1032, aims to provide a safer alternative to traditional corticosteroid therapies for various inflammatory and infectious diseases. The company is actively advancing its pipeline across multiple therapeutic areas, including rare diseases like Duchenne Muscular Dystrophy (DMD), as well as chronic inflammatory conditions such as psoriasis, arthritis, and multiple sclerosis. MetrioPharm leverages a unique mechanism of action that activates only in the presence of elevated reactive oxygen species (ROS), offering a targeted approach to inflammation management.